Stock listing
ASX:COV CLEO Diagnostics Ltd Share Price
Home listing (ASX) of CLEO Diagnostics Ltd
Follow CLEO Diagnostics Ltd into a list and get an email when it puts out news.
Share price · ASX:COV
$0.26 AUD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.245 – $0.26 AUDNov 20, 2026
- Volume
- 242,953 sharesNov 20, 2026
- Market cap
- $37.02M AUDAt the close on Nov 20, 2026 · price × 142.4M shares outstanding
- 52-week range
- $0.245 – $0.90 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $31,514 AUDMedian day 58,806 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:COV · Home | $0.26 AUD | 0.00 (0.0%) | 242,953 | $0.25 | $0.26 | $0.245 | $0.26 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:COV · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.26 | 0.00 | 0.0% | $0.25 | $0.26 | $0.245 | 242,953 | |
| $0.26 | -0.015 | -5.5% | $0.275 | $0.275 | $0.26 | 23,869 | |
| $0.275 | +0.005 | +1.9% | $0.275 | $0.275 | $0.275 | 10,004 | |
| $0.27 | 0.00 | 0.0% | $0.27 | $0.27 | $0.27 | 352 | |
| $0.27 | -0.02 | -6.9% | $0.29 | $0.29 | $0.27 | 154,653 | |
| $0.29 | +0.005 | +1.8% | $0.285 | $0.29 | $0.285 | 58,791 | |
| $0.285 | -0.015 | -5.0% | $0.29 | $0.29 | $0.28 | 37,015 | |
| $0.30 | +0.01 | +3.4% | $0.30 | $0.30 | $0.30 | 978 | |
| $0.29 | +0.02 | +7.4% | $0.28 | $0.29 | $0.28 | 30,527 | |
| $0.27 | -0.01 | -3.6% | $0.28 | $0.28 | $0.27 | 2,493 | |
| $0.28 | +0.005 | +1.8% | $0.285 | $0.285 | $0.275 | 73,627 | |
| $0.275 | -0.02 | -6.8% | $0.29 | $0.29 | $0.26 | 190,183 | |
| $0.295 | 0.00 | 0.0% | $0.295 | $0.295 | $0.295 | 45,025 | |
| $0.295 | 0.00 | 0.0% | $0.295 | $0.295 | $0.295 | 96 | |
| $0.295 | -0.005 | -1.7% | $0.30 | $0.30 | $0.295 | 140,150 | |
| $0.30 | +0.005 | +1.7% | $0.295 | $0.30 | $0.295 | 11,569 | |
| $0.295 | 0.00 | 0.0% | $0.295 | $0.30 | $0.295 | 58,780 | |
| $0.295 | -0.01 | -3.3% | $0.305 | $0.305 | $0.295 | 47,536 | |
| $0.305 | -0.015 | -4.7% | $0.305 | $0.305 | $0.293 | 85,936 | |
| $0.32 | +0.015 | +4.9% | $0.312 | $0.32 | $0.312 | 2,123 | |
| $0.305 | -0.01 | -3.2% | $0.305 | $0.315 | $0.30 | 68,808 | |
| $0.315 | +0.01 | +3.3% | $0.345 | $0.355 | $0.305 | 237,701 | |
| $0.305 | 0.00 | 0.0% | $0.305 | $0.305 | $0.305 | 6,938 | |
| $0.305 | -0.005 | -1.6% | $0.32 | $0.32 | $0.30 | 106,387 | |
| $0.31 | -0.01 | -3.1% | $0.31 | $0.31 | $0.31 | 2,000 | |
| $0.32 | -0.01 | -3.0% | $0.33 | $0.33 | $0.295 | 171,047 | |
| $0.33 | -0.015 | -4.3% | $0.34 | $0.34 | $0.315 | 78,853 | |
| $0.345 | -0.005 | -1.4% | $0.35 | $0.36 | $0.33 | 204,569 | |
| $0.35 | +0.035 | +11.1% | $0.32 | $0.35 | $0.31 | 128,274 | |
| $0.315 | +0.005 | +1.6% | $0.315 | $0.32 | $0.315 | 58,821 | |
| $0.31 | -0.01 | -3.1% | $0.315 | $0.315 | $0.31 | 25,303 | |
| $0.32 | -0.03 | -8.6% | $0.35 | $0.35 | $0.32 | 6,611 | |
| $0.35 | 0.00 | 0.0% | $0.34 | $0.35 | $0.34 | 1,500 | |
| $0.35 | +0.005 | +1.4% | $0.335 | $0.35 | $0.335 | 25,547 | |
| $0.345 | +0.025 | +7.8% | $0.32 | $0.345 | $0.315 | 202,365 | |
| $0.32 | +0.035 | +12.3% | $0.305 | $0.32 | $0.295 | 123,565 | |
| $0.285 | +0.005 | +1.8% | $0.285 | $0.30 | $0.285 | 77,261 | |
| $0.28 | -0.01 | -3.4% | $0.29 | $0.29 | $0.28 | 48,985 | |
| $0.29 | -0.005 | -1.7% | $0.295 | $0.295 | $0.28 | 91,791 | |
| $0.295 | 0.00 | 0.0% | $0.295 | $0.295 | $0.27 | 570,452 | |
| $0.295 | -0.01 | -3.3% | $0.305 | $0.305 | $0.29 | 809,172 | |
| $0.305 | -0.025 | -7.6% | $0.32 | $0.32 | $0.295 | 133,221 | |
| $0.33 | +0.03 | +10.0% | $0.31 | $0.335 | $0.31 | 224,917 | |
| $0.30 | -0.01 | -3.2% | $0.31 | $0.315 | $0.295 | 189,247 | |
| $0.31 | -0.015 | -4.6% | $0.32 | $0.32 | $0.31 | 50,203 | |
| $0.325 | +0.01 | +3.2% | $0.315 | $0.325 | $0.293 | 197,552 | |
| $0.315 | +0.005 | +1.6% | $0.32 | $0.325 | $0.315 | 17,760 | |
| $0.31 | -0.025 | -7.5% | $0.34 | $0.345 | $0.31 | 130,740 | |
| $0.335 | +0.02 | +6.3% | $0.34 | $0.34 | $0.335 | 27,580 | |
| $0.315 | -0.025 | -7.4% | $0.325 | $0.325 | $0.315 | 172,265 | |
| $0.34 | 0.00 | 0.0% | $0.33 | $0.355 | $0.325 | 154,485 | |
| $0.34 | -0.01 | -2.9% | $0.34 | $0.34 | $0.33 | 94,543 | |
| $0.35 | -0.005 | -1.4% | $0.355 | $0.355 | $0.35 | 54,100 | |
| $0.355 | -0.03 | -7.8% | $0.37 | $0.37 | $0.355 | 33,835 | |
| $0.385 | -0.015 | -3.8% | $0.41 | $0.42 | $0.36 | 126,308 | |
| $0.40 | +0.05 | +14.3% | $0.395 | $0.40 | $0.385 | 50,247 | |
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 0 | |
| $0.35 | +0.005 | +1.4% | $0.345 | $0.36 | $0.34 | 62,943 | |
| $0.345 | 0.00 | 0.0% | $0.345 | $0.345 | $0.345 | 27,934 | |
| $0.345 | +0.005 | +1.5% | $0.34 | $0.345 | $0.325 | 204,681 | |
| $0.34 | -0.02 | -5.6% | $0.335 | $0.35 | $0.335 | 12,277 | |
| $0.36 | +0.005 | +1.4% | $0.345 | $0.36 | $0.34 | 57,676 | |
| $0.355 | +0.015 | +4.4% | $0.345 | $0.355 | $0.335 | 57,510 | |
| $0.34 | +0.023 | +7.1% | $0.325 | $0.34 | $0.325 | 132,816 | |
| $0.318 | -0.013 | -3.8% | $0.32 | $0.323 | $0.315 | 39,565 | |
| $0.33 | 0.00 | 0.0% | $0.34 | $0.34 | $0.33 | 135,142 |
- Ticker
- ASX:COV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 11, 2026
CLEO Advances Toward Clinical Validation
Latest news
CLEO Advances Toward Clinical Validation
Nov 11, 2026
Closed $0.29 (+1.8%) on Nov 12, 2026
Quarterly activities and cashflow report
Oct 30, 2026
Closed $0.295 (0.0%) on Nov 2, 2026
CLEO Screening Test Meets Rigorous Performance Targets
Oct 20, 2026
Closed $0.315 (+3.3%) on Oct 21, 2026
CLEO Commences Analytical Validation Ahead of FDA Submission
Oct 12, 2026
Closed $0.345 (-1.4%) on Oct 13, 2026
Cleo Files Patents for its Ovarian Cancer Screening Test
Sep 29, 2026
Closed $0.285 (+1.8%) on Sep 30, 2026
CLEO Commences Ovarian Cancer Screening Test Development
Sep 23, 2026
Closed $0.295 (-3.3%) on Sep 24, 2026
Letter to Shareholders
Sep 16, 2026
Closed $0.325 (+3.2%) on Sep 17, 2026
Notice of Annual General Meeting/Proxy Form
Sep 16, 2026
Closed $0.325 (+3.2%) on Sep 17, 2026
Notice Required Under ASX Listing Rule 3.13.1
Sep 10, 2026
Closed $0.315 (-7.4%) on Sep 11, 2026
CLIA Certified Lab selected - Pivotal US Clinical Validation
Sep 9, 2026
Closed $0.34 (0.0%) on Sep 10, 2026
CLEO Diagnostics Ltd on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 32 in the last 12 months · 60 in all · newest Nov 11, 2026 · oldest 2023
- Decks
- 2 decks · latest Jun 12, 2025
Where CLEO Diagnostics Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:COV · Home listing · This page | ASX | Australia | AUD |
| OTC:CLDGF | OTC | United States | USD |
Valuation
Price/book 7.4× against a median of 1.0×: the highest of 11 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $30.80M AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 7.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CLEO Diagnostics Ltd · ASX:COV | US$24.57M | US$20.44M | n/a | n/a | n/a | 7.4× | n/a | 0.0× | n/a |
| Bioptic Inc. · TPEX:6850 | US$26.11M | US$22.55M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | n/a |
| genOway SA · EURONEXT:ALGEN | US$25.87M | US$38.95M | 25.4× | 1.7× | 8.7× | 1.1× | 4.4% | 0.7× | n/a |
| Orientbio, Inc. · KRX:002630 | US$25.03M | −US$3.27M | 14.6× | −0.1× | −0.8× | 0.5× | 8.1% | 0.0× | n/a |
| Clever Culture Systems Limited · ASX:CC5 | US$24.62M | US$25.47M | n/a | 8.3× | n/a | 4.9× | −48.4% | 0.4× | n/a |
| Genesystem Co., Ltd. · KRX:363250 | US$24.54M | US$22.35M | n/a | 29.8× | n/a | 2.8× | n/a | 0.2× | n/a |
| C&R Research Inc. · KRX:359090 | US$23.87M | US$12.44M | 19.3× | 0.3× | 23.4× | 0.7× | 2.6% | 0.0× | n/a |
| HLB Panagene Co. Ltd. · KRX:046210 | US$23.55M | US$6.15M | n/a | 0.6× | n/a | 0.4× | −22.3% | 0.0× | n/a |
| IMBdx, Inc. · KRX:461030 | US$23.49M | US$10.14M | n/a | 2.4× | n/a | 1.4× | −135.5% | 0.0× | n/a |
| QuantaMatrix, Inc. · KRX:317690 | US$23.36M | US$881,618 | n/a | 0.4× | n/a | 1.0× | −567.5% | 0.0× | n/a |
| Genolution Inc. · KRX:225220 | US$23.33M | US$3.40M | n/a | 0.5× | n/a | 0.5× | −46.5% | 0.0× | n/a |
| Median of the others | US$24.21M | US$11.29M | 19.3× | 0.6× | 8.7× | 1.0× | −34.4% | 0.0× |
Team and board
Officers
| Officer | Role |
|---|---|
| Richard Allman | Chief Executive Officer and Executive Director |
| Pauline Moffatt | Company Secretary |
| Andrew Stephens | Chief Scientific Officer and Executive Director |
Board
| Director | Role |
|---|---|
| Adrien Wing | Non-Executive Chair |
| Andrew Stephens | Chief Scientific Officer and Executive Director |
| Lucinda Nolan | Non-Executive Director |
| Richard Allman | Chief Executive Officer and Executive Director |
| Tom Jobling | Lead Medical Advisor and Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 26, 2025 | −0.7% |
| Q2 2025 | Feb 27, 2025 | −6.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2025) | Investor deck | 22 slides | Jun 12, 2025 |
| Investor Presentation (February 2024) | Investor deck | 21 slides | Feb 20, 2024 |
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.18M | 600.1K | 110.1K | 0 | |
| Selling, general and administrative | 2.49M | 2.14M | 1.58M | 1.39M | |
| Operating income | -7.89M | -3.90M | -3.61M | -1.58M | -23.3K |
| Depreciation and amortization | 64.4K | 60.5K | 59.2K | 43.8K | |
| EBITDA | -7.82M | -3.84M | -3.55M | -1.53M | |
| Interest expense | 26.5K | 110.8K | |||
| Income before tax | -5.94M | -4.00M | -3.76M | -1.73M | -43.9K |
| Net income | -5.94M | -4.00M | -3.76M | -1.73M | -43.9K |
| Earnings per share, basic | -0.04 | -0.03 | -0.03 | -0.01 | -0.00 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cash and equivalents | 6.22M | 747.0K | 7.32M | 239.8K | 42.8K |
| Receivables | 70.6K | 57.4K | 31.9K | 860 | |
| Current assets | 6.34M | 6.55M | 9.44M | 580.2K | 43.6K |
| Property, plant and equipment | 32.6K | 31.9K | 38.1K | ||
| Total assets | 6.68M | 6.94M | 9.88M | 1.08M | 243.6K |
| Accounts payable | 1.29M | 870.8K | 439.9K | 417.4K | |
| Current liabilities | 1.67M | 1.10M | 486.2K | 2.02M | 285.9K |
| Total liabilities | 1.67M | 1.10M | 486.2K | 2.02M | 285.9K |
| Shareholders' equity | 5.01M | 5.83M | 9.39M | -943.4K | -42.3K |
| Shares outstanding | 137.1M | 128.5M | 128.5M | 128.5M | 128.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Cash from operations | -2.90M | -2.03M | -684.5K | |
| Capital spending | -9.42K | -11.1K | -3.05K | -340.2K |
| Free cash flow | -4.95M | -2.91M | -2.03M | -1.02M |
| Cash from investing | -11.1K | -3.05K | -340.2K | |
| Cash from financing | 4.71M | 0 | 11.2M | 1.22M |
| Share buybacks | -373.2K | 0 | 12.0M | 0 |
| Change in cash | -236.5K | -2.91M | 9.13M | 197.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| CLEO Advances Toward Clinical Validation | Nov 11, 2026 | Operations update | ASX |
| Quarterly activities and cashflow report | Oct 30, 2026 | Quarterly report | ASX |
| Quarterly activities and cashflow report | Oct 30, 2026 | Quarterly report | ASX |
| CLEO Screening Test Meets Rigorous Performance Targets | Oct 20, 2026 | Operations update | ASX |
| CLEO Screening Test Meets Rigorous Performance Targets | Oct 20, 2026 | Operations update | ASX |
| CLEO Commences Analytical Validation Ahead of FDA Submission | Oct 12, 2026 | Operations update | ASX |
| Cleo Files Patents for its Ovarian Cancer Screening Test | Sep 29, 2026 | Other filings | ASX |
| CLEO Commences Ovarian Cancer Screening Test Development | Sep 23, 2026 | Operations update | ASX |
| Letter to Shareholders | Sep 16, 2026 | Meeting notice | ASX |
| Notice of Annual General Meeting/Proxy Form | Sep 16, 2026 | Meeting notice | ASX |
All 60 filings
Cap table
Built by 6ix from CLEO Diagnostics Ltd’s releases
- Common shares
- 142,383,746
- Fully diluted
- 142,383,746
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 142,383,746 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 142,383,746 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adrien Wing | Non-Executive Chair · Since at least Oct 12, 2026 |
| Andrew Stephens | Chief Scientific Officer and Executive Director · Since at least Nov 5, 2026 |
| Lucinda Nolan | Non-Executive Director · Since at least Nov 5, 2026 |
| Pauline Moffatt | Company Secretary · Since at least Nov 5, 2026 |
| Richard Allman | Chief Executive Officer and Executive Director · Since at least Oct 12, 2026 |
| Tom Jobling | Lead Medical Advisor and Non-Executive Director · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about CLEO Diagnostics Ltd.